Q-omics provides the consensus-scored ISG20 profile across patient tissues and cancer cell-line models. ISG20 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ISG20 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ISG20 protein abundance shows 23,076 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where ISG20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ISG20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ISG20 survival associations across molecular data types. ISG20 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ISG20 RNA expression–survival associations across cancer types. High ISG20 expression shows unfavorable associations in UVM, ACC and LGG, but favorable associations in SKCM, CESC and OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ISG20 RNA expression.
This table summarizes ISG20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ISG20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ISG20 shows lower tumor expression in THCA and LUSC and higher tumor expression in KIRC, KIRP, HNSC and LIHC. The KIRC box plot shows higher ISG20 RNA expression in tumor versus normal tissue (log2 FC = +1.752, t-test p < 0.001).
This table shows molecular features associated with ISG20 in patient tissues and cancer cell lines. In patient samples, ISG20 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ISG20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
